美国食品药品监督管理局已接受施贵宝（Bristol-Myers Squibb）提交的Camzyos（Mavacamten）补充新药申请，并授予其优先审评资格。该申请旨在扩展该药物的适应症，用于治疗青少年患者的症状性梗阻性肥厚型心肌病。
美国食品药品监督管理局已接受施贵宝（Bristol-Myers Squibb）提交的Camzyos（Mavacamten）补充新药申请，并授予其优先审评资格。该申请旨在扩展该药物的适应症，用于治疗青少年患者的症状性梗阻性肥厚型心肌病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.